L-kynurenine is the main metabolite of tryptophan, and tryptophan 2,3-dioxygenase inhibitors can effectively reduce L-kynurenine synthesis, delay tumor growth and metastasis, which mechanistically involves aryl hydrocarbon receptor (AHR)29. Here, TDO2 is linked to neoplasm.